Epigenetische Modifikationen in malignen Zellen

Zusammenfassung

Abstract

Schlüsselwörter

Epigenetik - DNA-Methylierung - Histone

Key words

epigenetics - DNA methylisation - histones

• Literatur

• 1 Almstedt M, Blagitko-Dorfs N, Duque-Afonso J et al. The DNA demethylating agent 5-aza-2´- deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res 2010; 34: 899-905
• 2 Borthakur G, Ahdab SE, Ravandi F et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008; 49: 690-695
• 3 Cashen AF, Schiller GJ, O'Donnell MR et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. Clin Oncol 2010; 28: 556-561
• 4 Fenaux P, Mufti GJ, Hellström-Lindberg E et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569
• 5 Fenaux P, Mufti GJ, Hellström-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232
• 6 Field T, Perkins J, Huang Y et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010; 45: 255-260
• 7 Flotho C, Claus R, Batz C et al. The DNA methyltransferase inhibitors azacitidine, Decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009; 23: 1019-1028
• 8 Garcia-Manero G, Yang H, Bueso-Ramos C et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-1066
• 9 Goodyear O, Agathanggelou A, Novitzky-Basso I et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010; 116: 1908-1918
• 10 Hackanson B, Guo Y, Lübbert M. The silence of the genes: epigenetic disturbances in haematopoietic malignancies. Expert Opin Ther Targets 2005; 9: 45-61
• 11 Issa JPJ, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009; 15: 3938-3946
• 12 Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-1803
• 13 Kornblith AB, Herndon 2nd JE, Silverman LR et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002; 20: 2441-2452
• 14 Kuendgen A, Schmid M, Schlenk R et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006; 106: 112-119
• 15 Ley TJ, Ding L, Walter MJ et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433
• 16 Lübbert M, Bertz H, Rüter B et al. Non-intensive treatment with low-dose 5-aza-2´- deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 2009; 44: 585-588
• 17 Lübbert M, Suciu S, Baila L et al. Low-dose decitabine vs. best supportive care in elderly patients with intermediate- or high-risk MDS ineligible for intensive chemotherapy: final results of the randomized phase III study of the EORTC Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; in press
• 18 Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011; 29: 475-486
• 19 Möller I, Blum S, Gattermann N et al. Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine. Ann Hematol 2009; 88: 1141-1144
• 20 Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-2440
• 21 Wagner J, Hackanson B, Lübbert M et al. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenet 2010; 1: 117-136